Khadafi: A Critical Review of Prenatal Supplement Safety, Efficacy, and Regulatory Oversight

What Is Khadafi?

Khadafi is a branded prenatal multivitamin supplement marketed in select U.S. retail pharmacies and online platforms since 2019. Unlike widely recognized brands such as Nature Made Prenatal Multi + DHA (USP-verified), Rainbow Light Prenatal One, or Thorne Basic Prenatal, Khadafi has not undergone United States Pharmacopeia (USP) verification, does not carry NSF Certified for Sport or ConsumerLab.com seal of approval, and lacks published peer-reviewed clinical trials supporting its formulation. Manufactured by Vitalis Labs LLC (registered with FDA FEI #3015724896), Khadafi is distributed exclusively through regional chains including H-E-B Pharmacy and select Walmart locations in Texas and Louisiana. As of Q2 2024, it is sold in two formulations: Khadafi Prenatal (tablet) and Khadafi Prenatal+DHA (softgel). Neither product appears in the NIH Office of Dietary Supplements’ Evidence-Based Practice Center database or the Cochrane Library’s systematic reviews on prenatal nutrition.

Ingredient Profile and Clinical Relevance

The Khadafi Prenatal tablet contains 22 ingredients, including 800 mcg dietary folate equivalents (DFE) from calcium L-5-methyltetrahydrofolate, 27 mg elemental iron (as ferrous bisglycinate chelate), 1,000 IU vitamin D3 (cholecalciferol), and 200 mg DHA (from algal oil). These values align closely with American College of Obstetricians and Gynecologists (ACOG) 2023 guidelines recommending at least 400–800 mcg folic acid or equivalent before conception and through the first trimester, 27 mg iron daily during pregnancy, and 200–300 mg DHA for fetal neurodevelopment. However, Khadafi’s inclusion of 50 mg vitamin B6 exceeds ACOG’s upper limit of 10 mg/day for routine use and approaches the Tolerable Upper Intake Level (UL) of 100 mg/day established by the Institute of Medicine (IOM).

Vitamin B6: Risk-Benefit Assessment

While vitamin B6 is commonly used to alleviate nausea in pregnancy, high-dose supplementation (>25 mg/day) carries documented risks. A 2022 retrospective cohort study published in American Journal of Obstetrics & Gynecology linked chronic intake ≥50 mg/day to sensory neuropathy in three pregnant participants, all reporting bilateral numbness and gait instability resolving after discontinuation. Khadafi’s 50 mg dose falls within the range associated with these adverse events and exceeds the 10–25 mg/day dosing used in randomized controlled trials evaluating efficacy for hyperemesis gravidarum (e.g., the 2018 PREGNANT Trial using 10 mg twice daily).

Folate Form and Bioavailability

Khadafi uses calcium L-5-methyltetrahydrofolate—the biologically active form of folate—as its sole folate source. This avoids reliance on dihydrofolate reductase, an enzyme whose activity may be reduced in up to 30–40% of individuals carrying common MTHFR C677T polymorphisms (per CDC NHANES data). However, the 800 mcg DFE dose does not differentiate between women with confirmed MTHFR variants and those without, nor does labeling indicate whether genetic testing is recommended prior to use. In contrast, Thorne’s Basic Prenatal provides 1,000 mcg methylfolate specifically for MTHFR-positive patients, while Nature Made delivers 800 mcg synthetic folic acid—less bioavailable but rigorously studied for neural tube defect prevention.

Regulatory Status and Manufacturing Transparency

Khadafi is classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994 and is therefore not subject to pre-market FDA approval. Vitalis Labs LLC maintains current Good Manufacturing Practice (cGMP) certification per FDA 21 CFR Part 111, verified during a March 2023 inspection that cited no major deficiencies. However, the company does not publicly disclose batch-specific Certificate of Analysis (CoA) data, heavy metal testing thresholds, or microbiological assay results—unlike competitors such as MegaFood Baby & Me 2, which publishes full CoAs on its website showing lead <0.1 ppm, mercury <0.01 ppm, and arsenic <0.2 ppm per batch.

FDA Adverse Event Reporting Data

From January 2020 through June 2024, the FDA’s FAERS database logged 47 unique adverse event reports associated with Khadafi products. Of these, 19 involved gastrointestinal distress (nausea, constipation, abdominal cramping), 12 reported allergic reactions (pruritus, urticaria, angioedema), and 7 described neurological symptoms—including 3 cases of transient paresthesia attributed to high-dose B6. Notably, 9 reports were classified as ‘serious’ per FDA criteria (requiring hospitalization or resulting in persistent disability), including one case of iron-induced hemochromatosis in a woman with undiagnosed hereditary hemochromatosis (HFE C282Y homozygosity). No fatalities were reported. For comparison, Nature Made Prenatal Multi + DHA registered 212 FAERS reports over the same period—but with a market share approximately 17× larger, yielding a proportional rate of 0.012 events per 1,000 units sold versus Khadafi’s 0.048.

Third-Party Testing and Quality Verification

Independent laboratory analysis conducted by ConsumerLab.com in November 2023 tested five lots of Khadafi Prenatal+DHA softgels for potency, contaminants, and dissolution. Results revealed consistent delivery of labeled amounts of folate (98.3–102.1% of claimed 800 mcg DFE), iron (97.6–101.4% of 27 mg), and DHA (95.8–99.2% of 200 mg). However, cadmium levels averaged 1.23 ppm—exceeding California Proposition 65’s safe harbor level of 0.5 ppm for oral supplements—and lead concentrations ranged from 0.32 to 0.47 ppm, above the 0.1 ppm threshold recommended by the Council for Responsible Nutrition (CRN). No batches exceeded USP limits for microbial contamination (<1,000 cfu/g aerobic plate count; <10 cfu/g yeast/mold), but dissolution testing showed only 68% of iron released within 30 minutes in simulated gastric fluid—below the USP standard of ≥75% for ferrous salts.

Comparison With Industry Benchmarks

The following table compares key quality metrics across Khadafi and three leading prenatal brands:

Evidence From Clinical Studies

No prospective, randomized, placebo-controlled trials evaluating Khadafi’s impact on maternal or fetal outcomes have been published in PubMed-indexed journals. A single industry-sponsored pilot study (Vitalis Labs IRB #VL-2021-089) enrolled 42 low-risk pregnant participants aged 22–34 years between 8–12 weeks gestation. Participants received Khadafi Prenatal for 12 weeks; primary endpoints included serum ferritin, RBC folate, and incidence of iron deficiency anemia (IDA). Results—presented at the 2022 SMFM Annual Meeting but not peer-reviewed—showed mean ferritin increased from 28.3 ng/mL to 41.7 ng/mL (p=0.003), and RBC folate rose from 987 nmol/L to 1,422 nmol/L (p<0.001). However, the study lacked a comparator arm, excluded women with BMI ≥30 or prior IDA, and did not assess neonatal outcomes such as birth weight, gestational age at delivery, or Apgar scores.

In contrast, the landmark 2019 JAMA Pediatrics meta-analysis of 23 RCTs (n=15,212) found that prenatal multivitamins containing ≥30 mg iron reduced IDA incidence by 54% (RR 0.46, 95% CI 0.37–0.57) and increased mean birth weight by 42 g (95% CI 28–56 g). That analysis included data from trials using ferrous sulfate, ferrous fumarate, and ferrous bisglycinate—all forms shown to have differing absorption kinetics and GI tolerability profiles. Khadafi’s use of ferrous bisglycinate (a chelated form) theoretically improves absorption and reduces constipation, yet no head-to-head trials comparing Khadafi’s formulation to standard ferrous sulfate preparations exist.

DHA Dosage and Neurodevelopmental Outcomes

Khadafi supplies 200 mg DHA per daily dose—within the 200–300 mg range recommended by the Academy of Nutrition and Dietetics and the World Health Organization. However, recent evidence suggests dose-response relationships may be non-linear. The 2023 DOMInO trial follow-up (n=2,399 children at age 7) demonstrated that maternal supplementation with 800 mg DHA/day—double Khadafi’s dose—was associated with improved attention regulation and reduced hyperactivity compared to placebo (mean difference −2.1 points on Conners’ Rating Scale, p=0.02). While higher doses require further safety evaluation, Khadafi’s 200 mg may represent a conservative threshold rather than an optimized target for neurocognitive benefit.

Patient Counseling Considerations

As a doula and prenatal educator, I advise clients to evaluate prenatal supplements using four evidence-informed criteria: (1) alignment with ACOG/ACOG-endorsed nutrient targets; (2) transparency of third-party testing; (3) absence of ingredients exceeding ULs without clinical justification; and (4) documented safety in diverse populations—including those with comorbidities like thalassemia trait, celiac disease, or chronic kidney disease. Khadafi meets criterion #1 for most nutrients but fails criterion #3 due to its 50 mg B6 dose and criterion #2 due to non-public CoA data.

For clients seeking alternatives with comparable pricing ($24.99 for 60 tablets vs. $29.99 for Nature Made’s 90-count bottle), I routinely recommend Nature Made Prenatal Multi + DHA (USP-verified, iron dissolution ≥89%, cadmium <0.1 ppm) or Seeking Health Optimal Prenatal (methylfolate-based, B6 at 10 mg, full CoA disclosure). Clients with confirmed MTHFR variants may benefit from higher-dose methylfolate regimens prescribed by their OB-GYN or maternal-fetal medicine specialist—not over-the-counter formulations alone.

It is critical to emphasize that prenatal vitamins do not replace whole-food nutrition. A 2021 study in JAMA Network Open (n=1,852) found that women consuming ≥5 servings/day of fruits and vegetables had 32% lower risk of small-for-gestational-age infants—even when taking prenatal supplements—underscoring the irreplaceable role of dietary pattern.

Red Flags Requiring Immediate Discontinuation

Any client using Khadafi should discontinue use and contact their provider immediately if experiencing:

• Neurological symptoms including tingling, burning, or numbness in hands or feet
• Unexplained fatigue accompanied by pale skin, shortness of breath, or dizziness (possible iron overload or hemolysis)
• Severe or persistent nausea/vomiting unrelieved by dietary modification
• Development of rash, swelling of lips/tongue, or wheezing (signs of hypersensitivity)
• Dark urine or jaundice (potential hepatic involvement)

Practical Guidance for Healthcare Providers

Obstetric providers should document prenatal supplement use at every visit using standardized fields in EHR systems (e.g., Epic’s ‘Supplement Use’ SmartPhrase). When reviewing Khadafi labels, clinicians must verify iron content against patient-specific needs: women with thalassemia trait require no supplemental iron; those with chronic kidney disease stage 3+ may need dose adjustment due to impaired erythropoietin synthesis; and patients on proton-pump inhibitors (e.g., omeprazole 20 mg daily) experience ~30% reduced non-heme iron absorption—potentially necessitating alternate formulations or timing adjustments.

Pharmacists play a vital gatekeeping role. At H-E-B Pharmacy locations where Khadafi is stocked, pharmacists are required by Texas State Board of Pharmacy Rule §295.10 to provide written counseling on B6-related neuropathy risks when dispensing products containing ≥25 mg vitamin B6. Yet observational audits conducted in Q1 2024 found only 41% of Khadafi transactions included this counseling—a gap requiring targeted quality improvement initiatives.

Community health workers and doulas should reinforce messaging around supplement literacy. In a 2023 Houston-based focus group (n=32 low-income pregnant participants), 68% could not correctly identify ‘methylfolate’ versus ‘folic acid,’ and 81% believed ‘natural’ labeling implied regulatory oversight. Clear, visual handouts—such as the CDC’s ‘Choosing a Prenatal Vitamin’ fact sheet—should accompany all supplement discussions.

Key Questions to Ask Before Choosing Any Prenatal

1. Is the product verified by USP, NSF, or ConsumerLab.com?
2. Does the label specify forms of nutrients (e.g., ferrous bisglycinate vs. ferrous sulfate; methylfolate vs. folic acid)?
3. Are heavy metal test results publicly available for the specific lot number?
4. Does the iron dose match my clinical needs—or exceed them unnecessarily?
5. Has this product been studied in populations similar to mine (e.g., Black, Hispanic, or Asian women, who experience higher rates of folate insufficiency and iron deficiency)?

Ultimately, prenatal nutrition is foundational—but not infallible. No supplement can compensate for inadequate caloric intake, uncontrolled gestational diabetes, or untreated depression. Khadafi offers a clinically plausible nutrient profile for many low-risk pregnancies, yet its elevated B6 content, lack of public quality documentation, and absence of outcome-based research warrant cautious, individualized decision-making. Patients deserve transparency—not just marketing claims—and providers bear responsibility for translating complex regulatory and biochemical data into actionable, compassionate care.

For ongoing updates, clinicians and patients may consult the FDA’s searchable dietary supplement catalog (accessed via accessdata.fda.gov) and the NIH Office of Dietary Supplements’ Prenatal Vitamin Fact Sheet (updated March 2024).

Public health surveillance remains essential. The CDC’s Pregnancy Risk Assessment Monitoring System (PRAMS) now includes supplemental questions on prenatal vitamin brand selection, reasons for choice, and perceived barriers to adherence—data expected to inform future guidance from the U.S. Preventive Services Task Force (USPSTF) on universal versus targeted supplementation strategies.

At the core of evidence-based prenatal care lies humility: acknowledging that what we prescribe today may be refined tomorrow by new data, better assays, or deeper understanding of epigenetic interactions. Until then, vigilance, transparency, and patient-centered dialogue remain our strongest tools.

Providers should also note that Khadafi’s packaging states ‘Not evaluated by the FDA’ in 6-point font on the back panel—a legally required disclaimer, but one easily overlooked. Legibility standards for OTC supplement labeling remain inconsistent; the FDA’s proposed 2025 rulemaking aims to mandate minimum 8-point font for all active ingredient disclosures, a change that would significantly improve informed consent.

Finally, cost remains a barrier. While Khadafi retails at $24.99, Medicaid-covered alternatives like Vitafol-OB ($12.49 co-pay in Texas) and state WIC-approved options (e.g., Enfamil Prenatal DHA at $9.99 via WIC voucher) offer comparably validated formulations at lower out-of-pocket expense. Doula programs funded through HRSA’s Healthy Start Initiative routinely assist clients in accessing these resources—demonstrating how structural support amplifies individual choice.

The landscape of prenatal supplementation continues to evolve rapidly. As new delivery technologies emerge—including nanoemulsified DHA and time-release iron matrices—rigorous independent evaluation must precede widespread adoption. Khadafi serves as a case study in why consumer advocacy, regulatory modernization, and clinician education must advance in tandem.

For clients navigating this terrain, I offer this principle: Your body knows more than any label. Track your energy, digestion, mood, and lab trends—not just the pill bottle. And never hesitate to ask, ‘What evidence supports this recommendation—for someone exactly like me?’ That question, asked with kindness and persistence, transforms passive consumption into empowered partnership.